Eli Lilly's Q2 Sales Surge 36%, Analysts Cautious On Future Supply, Market Dynamics; Optimistic About Next-Gen Oral Weight-Loss Drug
Eli Lilly's Q2 Sales Surge 36%, Analysts Cautious On Future Supply, Market Dynamics; Optimistic About Next-Gen Oral Weight-Loss Drug
Eli Lilly And Co (NYSE:LLY) reported on Thursday second-quarter revenue of $11.3 billion, up 36% year-over-year, easily surpassing the consensus of $9.95 billion.
禮來（紐交所：LLY）週四報告了2012年第二季度營業收入達113億美元，同比增長36%，輕鬆超過了預期的995億美元。
Mounjaro sales tripled to $3.09 billion from $979.7 million a year ago. Zepbound sales reached $1.24 billion, up from $517.4 million reported in the first quarter of 2024 since it received FDA approval in November 2023.
從一年前的9797萬美元增長到了309億美元，蒙賈羅銷售額翻了三倍，澤普邦德銷售額達到了124億美元，高於2024年第一季度的5174萬美元，因爲它在2023年11月獲得FDA批准。
Goldman Sachs noted that Eli Lilly's second-quarter performance benefited from better channel dynamics and clearer manufacturing processes. However, they warned that rising demand might lead to occasional supply shortages for specific presentations and dose levels.
高盛指出，禮來的第二季度表現受益於更好的渠道動態和更清晰的製造工藝。然而，他們警告稱，需求上升可能會導致特定品種和劑量水平偶爾出現供應短缺。
"The guidance raise is impressive," the analyst Chris Shibutani adds, raising the price target to $856 from $812.
分析師克里斯·渋山談到：「預測的收盤行情令人印象深刻」，將價格目標從812美元上調到856美元。
The analyst maintains a Neutral rating as Goldman Sachs is closely watching the narrowing supply/demand gap, which reassures them about execution but raises questions about the total addressable market (TAM), competitor pipeline programs and the sustainability of pricing dynamics amid heightened expectations following recent results.
分析師維持中立評級，因爲高盛正在密切關注供需縮小的差距，這使他們對執行感到放心，但又對總可尋市場（TAM）、競爭對手的管道項目和隨着近期結果引發的期望升溫而持續的定價動態的可持續性提出了疑問。
Truist Securities says Mounjaro and Zepbound continue to outperform.
Truist Securities表示，蒙賈羅和澤普邦德繼續表現突出。
"We believe the recent lift of tirzepatide from the FDA shortage list could support a leadership position in obesity/diabetes management," analyst Srikripa Devarakonda adds.
分析師Srikripa Devarakonda補充道：「我們認爲，最近將Tirzepatide從FDA短缺的列表中刪除可能會支持肥胖症/糖尿病管理領域的領先地位。」
The analyst notes that tirzepatide could potentially be expanded for use in obstructive sleep apnea, osteoarthritis, cardiovascular issues, and renal conditions. They also see the potential for growth from upcoming developments, such as orforglipron, an oral GLP-1 for weight loss. Eli Lilly continues to invest in research and development across its main therapeutic areas to broaden its portfolio beyond its type 2 diabetes and obesity treatments.
分析師指出，Tirzepatide有望在阻塞性睡眠呼吸暫停、骨關節炎、心血管問題和腎病等領域進行擴展應用。他們還看到未來發展的潛力，例如Orforglipron，這是一種口服GLP-1，用於減肥。
Truist maintains the Buy rating with a price target of $1,000.
Truist維持買入評級，目標價1000美元。
Damien Conover, Morningstar director of healthcare equity research, also increased the fair value estimate for "wide moat" Eli Lilly to $580 from $540. "However, we believe the stock still looks overvalued," the analyst adds.
晨星醫療保健股權研究主管達米安·康諾弗還將「寬壕」禮來的公平價值評估從540美元上調至580美元。分析師補充說：「然而，我們認爲股票仍然有些高估。」
The analyst forecasts strong sales for Mounjaro and Zepbound but believes the market is overly optimistic. Factors such as anticipated price drops, high patient costs, future competition beyond Novo Nordisk A/S (NYSE:NVO), tolerability concerns, and potential long-term safety issues might not be fully considered.
分析師預測，蒙賈羅和澤普邦德的銷售業績強勁，但認爲市場過於樂觀。預計價格下降、高昂的患者成本、諾和諾德公司（NYSE：NVO）以外的未來競爭、耐受性擔憂和潛在的長期安全問題等因素可能沒有被充分考慮。
On the pipeline, Morningstar is bullish on Eli Lilly's next-generation oral weight-loss drug, orforglipron.
在管道方面，晨星對禮來的下一代口服減肥藥物Orforglipron持看好態度。
The recent launch of the Alzheimer's drug Kisunla has the potential to become a major blockbuster, though Morningstar analyst anticipates a gradual increase in its market uptake.
最近推出的阿爾茨海默病藥物Kisunla有望成爲一個主要的暢銷品，不過晨星分析師預計其市場佔有率將逐步增加。
LLY Price Action: Eli Lilly And Co. stock is up 5.58% at $892.50 at last check Friday.
LLY股票價格：禮來（Eli Lilly And Co）股票在上週五最後一次查詢時以892.50美元上漲了5.58%。
- Eli Lilly's Zepbound Challenges Novo Nordisk's Wegovy Amid Supply Issues.
- 伊利製藥的Zepbound在供應問題中挑戰諾和諾德的Wegovy。
Photo: Rafapress on Shutterstock
圖片來源：Shutterstock上的Rafapress